Novo Nordisk closer to launch of prize asset in Europe following new approval
Changes in the pricing strategy for Novo Nordisk's new drug hope Ozempic have caused larger regulatory problems in the EU than expected, and have impacted the launch in European countries. But the pharmaceutical company has just received an important approval, which will enable a launch in the second half of the year.
Earlier this year, Novo Nordisk launched its long-acting GLP-1 analog Ozempic on the US market, but the launch in Europe has been much slower.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
